A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)

Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled, A Multicenter, Randomized, Double-blind, Placebo-controlled, 3 Parallel Groups, Phase 2 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Oltipraz in Patients With Non-alcoholic Fatty Liver Disease (Except Liver Cirrhosis)

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Feb 2017

At a glance

  • Drugs Oltipraz (Primary)
  • Indications Non-alcoholic fatty liver disease
  • Focus Therapeutic Use
  • Sponsors PharmaKing
  • Most Recent Events

    • 22 Feb 2017 Primary endpoint of change in quantity of liver fat concentration assessed by MRS has been met, according to results published in the Alimentary Pharmacology and Therapeutics.
    • 22 Feb 2017 Results published in the Alimentary Pharmacology and Therapeutics
    • 22 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top